Concord Biotech

Concord Biotech Current Liabilities

The Current Liabilities of Concord Biotech (CONCORDBIO.NS) as of Oct 18, 2026 is 1.69 B INR. In the previous year, Current Liabilities was 1.86 B INR — a change of -9.29% (lower).

Current Liabilities

1.69 BINR

YoY

-9.29%

Last updated:

Current Liabilities of Concord Biotech is 2026 1.69 B INR. Current Liabilities of Concord Biotech was 2025 1.86 B INR. It decreases by -9.29% lower compared to the previous year.

The Concord Biotech Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2020
1.29 B INR
Jan 1, 2021
1.33 B INR
Jan 1, 2022
1.82 B INR
Jan 1, 2023
2.08 B INR
Jan 1, 2024
1.41 B INR
Jan 1, 2025
1.86 B INR
Jan 1, 2026
1.69 B INR
The Concord Biotech Current Liabilities history
YEARCurrent LiabilitiesYoY
1.69 BINR-9.29%
1.86 BINR+32.24%
1.41 BINR-32.31%
2.08 BINR+14.32%
1.82 BINR+37.44%
1.33 BINR+2.99%
1.29 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Concord Biotech Stock analysis

What does Concord Biotech do? Concord Biotech Ltd is a pharmaceutical company headquartered in Ahmedabad, India. It operates in the Health Care sector with a focus on Pharmaceuticals. The company went public via an IPO on August 18, 2023. Concord Biotech develops and manufactures active pharmaceutical ingredients (APIs) using fermentation and semi-synthetic processes. It produces finished formulations and APIs for therapeutic areas including immunosuppressants, anti-bacterial, oncology, and anti-fungal treatments. The company's API portfolio includes Mycophenolate Mofetil, Cyclosporine, Vancomycin Hydrochloride, and others. It also has a pipeline of API products under development such as Polymyxin B and Fidaxomicin. Concord Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Concord Biotech stock

Current Liabilities of Concord Biotech is 1.69 B INR in 2026.

Current Liabilities of Concord Biotech changed from 1.86 B INR to 1.69 B INR, representing a -9.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Concord Biotech since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Concord Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Concord Biotech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Concord Biotech